Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice.

Yamamoto T, Harada-Shiba M, Nakatani M, Wada S, Yasuhara H, Narukawa K, Sasaki K, Shibata MA, Torigoe H, Yamaoka T, Imanishi T, Obika S.

Mol Ther Nucleic Acids. 2012 May 15;1:e22. doi: 10.1038/mtna.2012.16.

2.

PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates.

Lindholm MW, Elmén J, Fisker N, Hansen HF, Persson R, Møller MR, Rosenbohm C, Ørum H, Straarup EM, Koch T.

Mol Ther. 2012 Feb;20(2):376-81. doi: 10.1038/mt.2011.260. Epub 2011 Nov 22.

3.

A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo.

Gupta N, Fisker N, Asselin MC, Lindholm M, Rosenbohm C, Ørum H, Elmén J, Seidah NG, Straarup EM.

PLoS One. 2010 May 17;5(5):e10682. doi: 10.1371/journal.pone.0010682.

4.

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates.

Frank-Kamenetsky M, Grefhorst A, Anderson NN, Racie TS, Bramlage B, Akinc A, Butler D, Charisse K, Dorkin R, Fan Y, Gamba-Vitalo C, Hadwiger P, Jayaraman M, John M, Jayaprakash KN, Maier M, Nechev L, Rajeev KG, Read T, Röhl I, Soutschek J, Tan P, Wong J, Wang G, Zimmermann T, de Fougerolles A, Vornlocher HP, Langer R, Anderson DG, Manoharan M, Koteliansky V, Horton JD, Fitzgerald K.

Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11915-20. doi: 10.1073/pnas.0805434105. Epub 2008 Aug 11.

5.

Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice.

Graham MJ, Lemonidis KM, Whipple CP, Subramaniam A, Monia BP, Crooke ST, Crooke RM.

J Lipid Res. 2007 Apr;48(4):763-7. Epub 2007 Jan 22.

6.

Superior Silencing by 2',4'-BNA(NC)-Based Short Antisense Oligonucleotides Compared to 2',4'-BNA/LNA-Based Apolipoprotein B Antisense Inhibitors.

Yamamoto T, Yasuhara H, Wada F, Harada-Shiba M, Imanishi T, Obika S.

J Nucleic Acids. 2012;2012:707323. doi: 10.1155/2012/707323. Epub 2012 Sep 26.

7.

Locked nucleic acid antisense inhibitor targeting apolipoprotein C-III efficiently and preferentially removes triglyceride from large very low-density lipoprotein particles in murine plasma.

Yamamoto T, Obika S, Nakatani M, Yasuhara H, Wada F, Shibata E, Shibata MA, Harada-Shiba M.

Eur J Pharmacol. 2014 Jan 15;723:353-9. doi: 10.1016/j.ejphar.2013.11.004. Epub 2013 Nov 20.

PMID:
24269597
8.

Liver as a target for oligonucleotide therapeutics.

Sehgal A, Vaishnaw A, Fitzgerald K.

J Hepatol. 2013 Dec;59(6):1354-9. doi: 10.1016/j.jhep.2013.05.045. Epub 2013 Jun 12.

9.

Target gene knockdown by 2',4'-BNA/LNA antisense oligonucleotides in zebrafish.

Itoh M, Nakaura M, Imanishi T, Obika S.

Nucleic Acid Ther. 2014 Jun;24(3):186-91. doi: 10.1089/nat.2013.0464. Epub 2014 Jan 24.

PMID:
24460393
10.

Inhibition of bcl-xL expression by antisense oligonucleotides containing various bridged nucleic acids (BNAs).

Roongjang S, Takahashi K, Obika S, Imanishi T.

Nucleic Acids Symp Ser (Oxf). 2007;(51):113-4.

PMID:
18029612
11.

Quantitative evaluation of the improvement in the pharmacokinetics of a nucleic acid drug delivery system by dynamic PET imaging with (18)F-incorporated oligodeoxynucleotides.

Mukai H, Ozaki D, Cui Y, Kuboyama T, Yamato-Nagata H, Onoe K, Takahashi M, Wada Y, Imanishi T, Kodama T, Obika S, Suzuki M, Doi H, Watanabe Y.

J Control Release. 2014 Apr 28;180:92-9. doi: 10.1016/j.jconrel.2014.02.014. Epub 2014 Feb 22.

PMID:
24566256
12.

Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates.

Straarup EM, Fisker N, Hedtjärn M, Lindholm MW, Rosenbohm C, Aarup V, Hansen HF, Ørum H, Hansen JB, Koch T.

Nucleic Acids Res. 2010 Nov;38(20):7100-11. doi: 10.1093/nar/gkq457. Epub 2010 Jul 8.

13.

Treadmill Exercise Training Modulates Hepatic Cholesterol Metabolism and Circulating PCSK9 Concentration in High-Fat-Fed Mice.

Wen S, Jadhav KS, Williamson DL, Rideout TC.

J Lipids. 2013;2013:908048. doi: 10.1155/2013/908048. Epub 2013 Jun 19.

14.

Impact of 3'UTR genetic variants in PCSK9 and LDLR genes on plasma lipid traits and response to atorvastatin in Brazilian subjects: a pilot study.

Zambrano T, Hirata MH, Cerda Á, Dorea EL, Pinto GA, Gusukuma MC, Bertolami MC, Salazar LA, Hirata RD.

Int J Clin Exp Med. 2015 Apr 15;8(4):5978-88. eCollection 2015.

15.

Design, synthesis, and properties of 2',4'-BNA(NC): a bridged nucleic acid analogue.

Rahman SM, Seki S, Obika S, Yoshikawa H, Miyashita K, Imanishi T.

J Am Chem Soc. 2008 Apr 9;130(14):4886-96. doi: 10.1021/ja710342q. Epub 2008 Mar 15.

PMID:
18341342
16.

Development of a 2',4'-BNA/LNA-based siRNA for Dyslipidemia and Assessment of the Effects of Its Chemical Modifications In Vivo.

Wada S, Obika S, Shibata MA, Yamamoto T, Nakatani M, Yamaoka T, Torigoe H, Harada-Shiba M.

Mol Ther Nucleic Acids. 2012 Sep 18;1:e45. doi: 10.1038/mtna.2012.32.

17.

Assessment of configurations and chemistries of bridged nucleic acids-containing oligomers as external guide sequences: a methodology for inhibition of expression of antibiotic resistance genes.

Jackson A, Jani S, Sala CD, Soler-Bistué AJ, Zorreguieta A, Tolmasky ME.

Biol Methods Protoc. 2016 Mar;1(1). pii: bpw001. Epub 2016 Mar 1.

18.

BNANC Gapmers Revert Splicing and Reduce RNA Foci with Low Toxicity in Myotonic Dystrophy Cells.

Manning KS, Rao AN, Castro M, Cooper TA.

ACS Chem Biol. 2017 Sep 5. doi: 10.1021/acschembio.7b00416. [Epub ahead of print]

PMID:
28853853
19.

A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations.

Gadkar K, Budha N, Baruch A, Davis JD, Fielder P, Ramanujan S.

CPT Pharmacometrics Syst Pharmacol. 2014 Nov 26;3:e149. doi: 10.1038/psp.2014.47.

20.

A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations.

Gadkar K, Budha N, Baruch A, Davis JD, Fielder P, Ramanujan S.

CPT Pharmacometrics Syst Pharmacol. 2014 Nov;3(11):1-9. doi: 10.1038/psp.2014.47.

Supplemental Content

Support Center